AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16393735 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 25
Study 16393735 — intervention group
Group type: COMPARATOR
Intervention: Non-psychosocial therapy group
Number of subjects: 25
Study 15289705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.03 mg/kg
Number of subjects: 38
Study 15289705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15289705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam at 20.00 h
Number of subjects: 38
Study 15289705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam at 22.00 h
Number of subjects: 38
Study 15289705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam at 18.00 h
Number of subjects: 38
Study 11397963 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (5 doses at biweekly intervals), 3 gm/day mycophenolate mofetil for the first 6 months and 2 gm thereafter, conventional corticosteroid therapy
Number of subjects: 98
Study 11397963 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil, corticosteroids
Number of subjects: 98
Study 11397963 — intervention group
Group type: COMPARATOR
Intervention: CNI use (more than 7 days)
Number of subjects: 98
Study 11397963 — intervention group
Group type: COMPARATOR
Intervention: No CNI use
Number of subjects: 98
Study 11397963 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI avoidance regimen
Number of subjects: 98
Study 9431900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Number of subjects: 129
Study 9431900 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Number of subjects: 129
Study 9431900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days
Number of subjects: 129
Study 9431900 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days
Number of subjects: 129
Study 7904930 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker with no ISA)
Number of subjects: 21
Study 7904930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7904930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (non-selective blocker with ISA)
Number of subjects: 21
Study 7904930 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective blocker with ISA)
Number of subjects: 21
Study 3551493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease (pH-sensitive enteric-coated microspheres)
Number of subjects: 11
Study 3551493 — intervention group
Group type: COMPARATOR
Intervention: Pancreatin (conventional enteric-coated granules)
Number of subjects: 11
Study 29388815 — intervention group
Group type: EXPERIMENTAL
Intervention: Selepressin (various dosing strategies)
Number of subjects: 1800
Study 29388815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study 27008245 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 14
Study 27008245 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 24333157 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medical care management and behavioral risk factor reduction
Number of subjects: 214
Study 24333157 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 23394506 — intervention group
Group type: EXPERIMENTAL
Intervention: New epinephrine autoinjector
Number of subjects: 180
Study 23394506 — intervention group
Group type: COMPARATOR
Intervention: Old epinephrine autoinjector
Number of subjects: 180
Study 20588151 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (1 mg/min for patients < 70 kg, 2 mg/min for patients ≥ 70 kg)
Number of subjects: 42
Study 20588151 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (0.125% and hydromorphone 6 microg/mL at 10 mL/hr)
Number of subjects: 42
Study 20588151 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 42
Study 20588151 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 42
Study 16903880 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITN)
Number of subjects: 10726
Study 16903880 — intervention group
Group type: COMPARATOR
Intervention: Control (no net provision)
Number of subjects: 10726
Study 14994886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014 inch archwire
Number of subjects: 109
Study 14994886 — intervention group
Group type: COMPARATOR
Intervention: 0.016 inch archwire
Number of subjects: 109
Study 11708707 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g x kg(‐1) lean body mass)
Number of subjects: 40
Study 11708707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11708707 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40
Study 9481973 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% supplemental oxygen (O2)
Number of subjects: 46
Study 9481973 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrous oxide (N2O) and 50% O2
Number of subjects: 46
Study 7957514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg every 12 h for three consecutive days
Number of subjects: 5
Study 7957514 — intervention group
Group type: COMPARATOR
Intervention: Enoxacin 200 mg every 8 h for three consecutive days
Number of subjects: 5
Study 3596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release tiaprofenic acid 600 mg once daily
Number of subjects: 146
Study 3596867 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tablet tiaprofenic acid 300 mg twice daily
Number of subjects: 146
Study 3596867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 28256305 — intervention group
Group type: EXPERIMENTAL
Intervention: KinesioTape with tension
Number of subjects: 30
Study 28256305 — intervention group
Group type: COMPARATOR
Intervention: KinesioTape without tension (placebo)
Number of subjects: 30
Study 27306909 — intervention group
Group type: EXPERIMENTAL
Intervention: SurvivorCare (SC)
Number of subjects: 221
Study 27306909 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 221
Study 24594542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 23
Study 24594542 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 23
Study 22782384 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance exercise for the lower extremity (EG)
Number of subjects: 58
Study 22782384 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional group (TG)
Number of subjects: 58
Study 22782384 — intervention group
Group type: EXPERIMENTAL
Intervention: Power group (PG)
Number of subjects: 58
Study 22782384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid strength group (RG)
Number of subjects: 58
Study 22782384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid strength group (RG) and Power group (PG)
Number of subjects: 58
Study 22782384 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study 20169461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day for 6 months
Number of subjects: 47
Study 20169461 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) 0.5-1 g/m2 monthly for 6 months
Number of subjects: 47
Study 20169461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and IVC
Number of subjects: 47
Study 20169461 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 47
Study 18205656 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care (POC) by a dental hygienist
Number of subjects: 40
Study 18205656 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing and mouth rinsing by patients themselves according to the instructions of a nurse (control)
Number of subjects: 40
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and propofol 2.5 mg kg(‐1) (Group 1)
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg(‐1) (Group 2)
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and thiopental 5 mg kg(‐1) (Group 3)
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg(‐1) (Group 4)
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and etomidate 0.3 mg kg(‐1) (Group 5)
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 1
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 2
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 3
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 4
Number of subjects: 175
Study 16169891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 5
Number of subjects: 175
Study 15321934 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS, SE, RE during propofol infusion with remifentanil (Ce(REMI) 0, 2 or 4 ng ml(‐1))
Number of subjects: 60
Study 15321934 — intervention group
Group type: COMPARATOR
Intervention: BIS, SE, RE during propofol infusion without remifentanil (Ce(REMI) 0 ng ml(‐1))
Number of subjects: 60
Study 15321934 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS, SE, RE
Number of subjects: 60
Study 11377152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1% to 8%)
Number of subjects: 60
Study 11377152 — intervention group
Group type: COMPARATOR
Intervention: Halothane (0.5% to 5%)
Number of subjects: 60
Study 9218012 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 149
Study 9218012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 7967863 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples obtained via central venous catheter (CVC)
Number of subjects: 250
Study 7967863 — intervention group
Group type: COMPARATOR
Intervention: Blood samples obtained via venipuncture
Number of subjects: 250
Study 3671893 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) in fasting state
Number of subjects: 37
Study 3671893 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) with a protein-fat-rich breakfast
Number of subjects: 37
Study 3671893 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 a.m.
Number of subjects: 37
Study 3671893 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 p.m.
Number of subjects: 37
Study 3671893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing of 400, 800, and 1,200 mg of the ultrasustained-release theophylline preparation (Theo-1) for 3 days each in steady state
Number of subjects: 37
Study 29016481 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-regulatory exercise selection (AES)
Number of subjects: 17
Study 29016481 — intervention group
Group type: COMPARATOR
Intervention: Fixed exercise selection (FES)
Number of subjects: 17
Study 29373987 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS model (integrates early supported discharge planning with transitional care management, including nurse-led follow-up phone calls after 2, 30, and 60 days and an in-person clinic visit at 7-14 days)
Number of subjects: 95
Study 29373987 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study 27088487 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) ventilation
Number of subjects: 24
Study 27088487 — intervention group
Group type: COMPARATOR
Intervention: Pressure Control (PC) ventilation
Number of subjects: 24
Study 25907082 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine final kissing balloon
Number of subjects: 725
Study 25907082 — intervention group
Group type: COMPARATOR
Intervention: Leave-alone
Number of subjects: 725
Study 25907082 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush
Number of subjects: 725
Study 25907082 — intervention group
Group type: COMPARATOR
Intervention: Single-stent
Number of subjects: 725
Study 23748515 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 1681
Study 23748515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1681
Study 20563833 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection enhanced delivery (CED) of IL13‐PE38QQR
Number of subjects: 180
Study 20563833 — intervention group
Group type: COMPARATOR
Intervention: Gliadel Wafers (GW)
Number of subjects: 180
Study 17936910 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 1113
Study 17936910 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 1113
Study 17012691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group cognitive behavior stress management intervention
Number of subjects: 199
Study 17012691 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study 12594664 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon beam coagulation (ABC) applied to the cut surface of the hepatic ligaments and bare area of the retroperitoneum
Number of subjects: 60
Study 12594664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ABC applied)
Number of subjects: 60
Study 10737446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific guideline
Number of subjects: 900
Study 10737446 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific guideline
Number of subjects: 900
Study 10737446 — intervention group
Group type: COMPARATOR
Intervention: No guideline
Number of subjects: 900
Study 8959115 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim as an adjunct to antibiotics for the treatment of CAP
Number of subjects: 100
Study 8959115 — intervention group
Group type: COMPARATOR
Intervention: APACHE II classification system for severity of disease
Number of subjects: 100
Study 1307994 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 nopal capsules
Number of subjects: 20
Study 1307994 — intervention group
Group type: COMPARATOR
Intervention: 30 placebo capsules
Number of subjects: 20
Study 1307994 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 nopal capsules t.i.d. for one week
Number of subjects: 20
Study 1307994 — intervention group
Group type: COMPARATOR
Intervention: 10 placebo capsules t.i.d. for one week
Number of subjects: 20
Study 6698666 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium suppositories (equivalent to 500 mg naproxen)
Number of subjects: 11
Study 6698666 — intervention group
Group type: COMPARATOR
Intervention: naproxen suppositories (500 mg)
Number of subjects: 11
Study 6698666 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium suppositories
Number of subjects: 11
Study 6698666 — intervention group
Group type: COMPARATOR
Intervention: naproxen suppositories
Number of subjects: 11
Study 31204437 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Number of subjects: 12
Study 31204437 — intervention group
Group type: COMPARATOR
Intervention: Clinpro™ XT varnish
Number of subjects: 12
Study 28982882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and Gemcitabine (NG)
Number of subjects: 74
Study 28982882 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine and Cisplatin (NP)
Number of subjects: 74
Study 25794045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline plus background regimen (BBR)
Number of subjects: 0
Study 25794045 — intervention group
Group type: COMPARATOR
Intervention: Background regimen (BR)
Number of subjects: 0
Study 23939169 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (Di group)
Number of subjects: 63
Study 23939169 — intervention group
Group type: COMPARATOR
Intervention: Thulium laser (Thu group)
Number of subjects: 63
Study 23939169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 21866498 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-count goal setting
Number of subjects: 0
Study 21866498 — intervention group
Group type: COMPARATOR
Intervention: Monitoring step counts with pedometers (Control)
Number of subjects: 0
Study 19621729 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial 190 mL black coffee
Number of subjects: 6
Study 19621729 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 6
Study 16792761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment (585 nm)
Number of subjects: 8
Study 16792761 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone dipropionate (Dovobet) treatment
Number of subjects: 8
Study 14971969 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex group (complex exercises)
Number of subjects: 39
Study 14971969 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated group (2-kg dumbbells)
Number of subjects: 39
Study 14971969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 39
Study 11165422 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 0
Study 9412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg i.m. at 4-week intervals for 3 months)
Number of subjects: 67
Study 9412795 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg s.c. at 4-week intervals for 3 months)
Number of subjects: 67
Study 9412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg i.m.)
Number of subjects: 67
Study 9412795 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg s.c.)
Number of subjects: 67
Study 7693419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimen given at the earliest possible time interval after surgery
Number of subjects: 2795
Study 7693419 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy started 12 weeks before surgery
Number of subjects: 2795
Study 7693419 — intervention group
Group type: COMPARATOR
Intervention: Therapy initiated shortly (perioperatively) after surgery
Number of subjects: 2795
Study 2892430 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with lormetazepam (2 mg evening prior, 1 mg 2 hours prior) and propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40
Study 2892430 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40
Study 2892430 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional i.v. injection of fentanyl (3 micrograms/kg) prior to propofol
Number of subjects: 40
Study 2892430 — intervention group
Group type: COMPARATOR
Intervention: No premedication with lormetazepam and propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40
Study 31391297 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and high-intensity interval training (RT-HIIT)
Number of subjects: 240
Study 31391297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and high-intensity interval training (AT-HIIT)
Number of subjects: 240
Study 31391297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240
Study 30121291 — intervention group
Group type: EXPERIMENTAL
Intervention: fezakinumab
Number of subjects: 59
Study 30121291 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study 28267243 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 44
Study 28267243 — intervention group
Group type: COMPARATOR
Intervention: Control (non-Japanese patients)
Number of subjects: 44
Study 25636519 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-driven assistant push
Number of subjects: 41
Study 25636519 — intervention group
Group type: COMPARATOR
Intervention: Standard CC (single-rescuer group)
Number of subjects: 41
Study 25636519 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-driven assistant push
Number of subjects: 41
Study 23521386 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive outreach community management program
Number of subjects: 0
Study 23521386 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 22156354 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 20 mg and domperidone 3 x 10 mg for 2 weeks
Number of subjects: 60
Study 22156354 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 2 x 20 mg (control group)
Number of subjects: 60
Study 19662959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 0
Study 16678543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 16678543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 16678543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14717754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mammography centers with tools and systems for patient notification)
Number of subjects: 11
Study 14717754 — intervention group
Group type: COMPARATOR
Intervention: Control group (mammography centers without intervention)
Number of subjects: 11
Study 12212638 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.04 mg/kg)
Number of subjects: 0
Study 12212638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9794507 — intervention group
Group type: EXPERIMENTAL
Intervention: AUCs truncated at four times Tmax
Number of subjects: 2214
Study 9794507 — intervention group
Group type: EXPERIMENTAL
Intervention: AUCs truncated at 3*Tmax
Number of subjects: 2214